Results 101 to 110 of about 4,270,323 (214)

Microgravity effect on expressionofRaf kinase inhibitor protein on MCF-7 breast cancer cell line [PDF]

مجله علمی دانشگاه علوم پزشکی کردستان, 2019
Background and Aim: The living organisms on the earth are under the influence of natural gravity force and if this gravitational force changes, they will be affected by a unique shock.
Maryam Salavatifar, Zahra Hajebrahimi
doaj   +2 more sources

Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog)

, 2017
Raf-kinase inhibitor protein has been reported to inhibit both the Raf/mitogen extracellular signal–regulated kinase/extracellular signal–regulated kinase and nuclear factor kappa-light-chain of activated B cells pathways.
Stephanie Wottrich, SoHyun Lee, Benjamin Bonavida   +2 more
core   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Chemical genetics approach reveals the role of Raf kinase inhibitor protein in cell migration.

, 2006
Chemical genetics approach reveals the role of Raf kinase inhibitor protein in cell ...
Shoutian. Zhu (7981862)
core   +4 more sources

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Diet-induced RKIP downregulation disrupts PC/PE-ER homeostasis to drive MASLD

Nature Communications
High-fat diet (HFD) is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD), yet the molecular pathways that connect dietary fats to liver dysfunction remain unclear.
Mengjie Li, Qian Ou, Qiang Qin, Jiaxi Chen, Sen Yang, Jie Zhao, Hua Meng, Xu Li, Pinglong Xu, Cunqi Ye, Xiaojian Wang   +10 more
doaj   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

m6A‐Mediated Stabilization of MRPS23 Drives NSCLC Progression Via HSPA8 and ERK Signaling Modulation

Cancer Science, EarlyView.
MRPS23 mRNA is m6A‐methylated by WTAP and stabilized by IGF2BP3, leading to increased MRPS23 protein. MRPS23 physically interacts with HSPA8, and this interaction is functionally associated with activation of the RAS–RAF–MEK–ERK pathway, ultimately promoting NSCLC cell proliferation and tumor progression.
Sihong Le, Yitao Le, Xianshen Sha, Feng Qiu, Ling Zhang   +4 more
wiley   +1 more source

The Expression and Significance of RKIP in Lung Squamous Cell Carcinoma Tissues

Chinese Journal of Lung Cancer, 2011
Background and objective Raf kinase inhibitory protein (RKIP) belongs to the phosphatidylethanolamine binding protein (PEBP) family. RKIP is an endogenous inhibitor of the Raf-1-MEK1/2-ERK1/2 signaling pathway, NFkappaB signaling pathway and G protein ...
Haiyuan XU, Xin WANG, Wenxiang SHEN, Liqiang WANG, Gang SHEN, Minbin CHEN, Lina ZHOU   +6 more
doaj  

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source